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Severe gangrene in a patient with anti-RNP positive 
limited cutaneous systemic sclerosis/rheumatoid arthritis 
overlap syndrome caused by vasculopathy and vasculitis
Introduction
Systemic sclerosis (SSc) is an autoimmune rheumatic disease characterized by fibrosis of skin and internal 
organs. Vasculopathy presenting as Raynaud’s phenomenon (RP) may lead to digital ulceration and gan-
grene requiring urgent intravenous vasodilator therapy. SSc may also manifest features of other connective 
tissue diseases, known as SSc overlap syndromes.
We present a 55-year-old male with anti-U1RNP positive limited cutaneous systemic sclerosis (lcSSc)/rheu-
matoid arthritis (RA) overlap syndrome, who developed acute-onset acral ischemia leading to extensive 
gangrene. There were constitutional symptoms at the outset and a marked inflammatory response with 
no evidence of infection, suggesting a diagnosis of vasculitis on a background of vasculopathy. The case 
was notable for the rapid progression of gangrene, which then responded well to immunosuppression. 
Conventional management with vasodilators had proven to be unhelpful. Dry gangrene in this setting can 
be managed conservatively to avoid extensive amputation and a poor functional outcome.
Case Presentation
A 55-year-old male non-smoker presented acutely with fever, joint pain, and cold, painful extremities. He 
had a background of non-erosive RA diagnosed 6 years previously (rheumatoid factor positive, anti-cyclic 
citrullinated peptide negative). His condition had been well controlled with methotrexate until 2 years 
before this admission, when he developed features of an lcSSc overlap syndrome with RP, sclerodactyly, 
telangiectasia, and sicca symptoms. Anti-nuclear antibodies were positive (titer of 1:640) with anti-RNP 
(U1RNP) specificity.
On examination, the patient had cold digits with small joint synovitis of the hands and feet. The rest of the 
examination was unremarkable. Blood tests on admission showed a raised white cell count of 21.1×109/L 
(neutrophil count 17.8×109/L) and C-reactive protein (CRP) 301 mg/L, but were otherwise normal. A chest 
x-ray and urine dip showed no evidence of infection.
The initial management was with empirical intravenous antibiotics, oral corticosteroids (prednisolone 20 
mg od), and continuous prostaglandin analog (iloprost) infusion. The patient’s body temperature spiked, 
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Abstract
In this paper, we describe a case of a male patient with anti-U1RNP positive limited cutaneous sys-
temic sclerosis/rheumatoid arthritis overlap syndrome, who presented acutely with rapidly progres-
sive digital ischemia, which lead to extensive gangrene. Management with conventional vasodilator 
therapy was unsuccessful. There were constitutional symptoms and a marked inflammatory response 
in the absence of evidence of infection, implying a component of vasculitis underlying the presenta-
tion. Treatment with immunosuppression and intravenous immunoglobulin led to resolution of the 
inflammatory process with no further progression of tissue necrosis. Here we discuss pertinent issues 
raised by the case, including the management of digital ischemia and gangrene in this context and 
the relevance of the anti-U1RNP in systemic sclerosis overlap syndromes.
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and inflammatory markers rose further; the an-
tibiotic therapy was broadened. A transesoph-
ageal echocardiogram showed no vegetations, 
and multiple sets of blood cultures returned 
negative. Computed tomography of the chest, 
abdomen, and pelvis did not reveal an occult 
source of sepsis.
One week into admission, necrosis of the hands 
and feet developed. A therapeutic dose of 
low-molecular weight heparin was added along 
with clopidogrel, and iloprost infusion was up-
titrated. Despite this, there was further deterio-
ration in the extremities. A magnetic resonance 
angiography revealed no macrovascular occlu-
sions responsible for the upper or lower limb 
gangrene. The patient received treatment with 
three daily doses of intravenous methylpred-
nisolone (500 mg), and CRP fell to 153 mg/L. 
Unfortunately, by Day 10, wet gangrene of the 
lower limbs had developed, and the patient un-
derwent bilateral below-knee amputations.
Postoperatively, the patient was managed in 
the intensive care unit with prednisolone 60 mg 
daily and infusions of intravenous immunoglob-
ulin (IVIG) over 5 days. This led to demarcation 
of tissue gangrene with no further progression 
of necrosis (Figure 2a). Ulnar and radial pulses 
were strong. The CRP fell rapidly, and antibiot-
ics were stopped (Figure 1). Myco phenolate 
mofetil (MMF) was initiated for the treatment of 
presumed vasculitis (unfortunately despite the 
request of the medical team no operative speci-
mens were sent for histological analysis).
Further investigation had been unremarkable, 
including negative tests for anti-centromere/
anti-Scl70 antibodies, anti-neutrophil cytoplas-
mic antibody (ANCA), antiphospholipid anti-
bodies, cryoglobulins, and serology for viruses 
hepatitis B, C, and HIV. Lipid profile was within 
normal limits.
The patient was examined by a plastic surgeon, 
who advised amputation at both elbows. Fol-
lowing discussion, it was decided to continue 
conservative management as long as the pa-
tient’s gangrene remained dry, and to await au-
to-amputation. Over time, there was a slow but 
definite improvement in the more proximal 
areas of patient’s hands that had initially ap-
peared non-viable. He continued with monthly 
IVIG, a weaning dose of prednisolone, and va-
sodilator therapy including sildenafil. MMF was 
uptitrated to 1g BD. Rivaroxaban was added.
The patient was eventually discharged to reha-
bilitation following a 4-month admission and 
learned to use prostheses independently. Over 
the subsequent year, both of his fifth digits au-
to-amputated, but the remaining digits did not. 
He eventually proceeded with limited surgical 
resection of his remaining necrotic digits 18 
months after the acute presentation (Figure 2b). 
He remains in remission on medical therapy. The 
patient has significant functional impairment as a 
consequence of the hand gangrene and subse-
quent surgery to his fingers, but he manages well.
Discussion
We describe a case of severe gangrene in a 
patient with anti-U1RNP-positive lcSSc/RA 
overlap. The acute presentation was marked 
by fever, elevated inflammatory markers, and 
rapidly progressive acral ischemia leading to 
Figure 1. Graph showing C-reactive protein serum levels during first 50 days of admission with 
significant interventions noted
Figure 2. a, b. Necrotic hands 2 weeks after presentation-recommendation of the plastic sur-
geon at this juncture was amputation at the elbows (a); hands after limited surgical resection 
conducted following full recovery and long remission (b)
a
b
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gangrene. We felt that the case was best de-
scribed as a combination of vasculitis (fever, 
high CRP) in the setting of SSc-vasculopathy 
(pre-existing RP). While conventional vasodila-
tor strategies appeared to be of limited benefit, 
the combination of immunosuppression and 
IVIG was associated with improvement and 
eventual recovery. We discuss here a number 
of points raised.
It is unknown how many SSc patients develop 
critical ischemia; of 1168 patients attending 
the Royal Free Hospital in London, 1.6% devel-
oped critical digital ischemia, and 1.4% pro-
gressed to gangrene (1). Critical digital isch-
emia in patients with anti-U1RNP antibody is 
well recognized; the Digital Ulcers Outcome 
registry reported an incidence of gangrene 
of 24.6% (n=114) (2). The standard approach 
to the management of such cases should in-
clude an assessment for proximal vessel dis-
ease, consideration of coexistent disorders 
such as systemic lupus erythematosus (SLE), 
vasculitis, and cryoglobulinemia, and exclu-
sion of prothrombotic states and thrombo-
embolic disease. The management of such 
patients should comprise vasodilators in-
cluding intravenous prostanoid, treatment of 
concurrent sepsis, consideration of anti-plate-
let/anticoagulation, and where appropriate, 
surgical resection (3). In our patient, digital 
ischemia was refractory to all such therapies. 
Intravenous corticosteroids, followed by IVIG, 
were therefore commenced for a likely vascu-
litic component. The patient responded well 
to this with resolution of fever, normalization 
of inflammatory markers, and no further pro-
gression of the gangrene.
Of some interest, there is the possible role of 
IVIG in promoting stabilization of the inflam-
matory process. We decided to use it here due 
to its emerging role in the treatment of AN-
CA-associated vasculitis and for its potential 
utility in the management of various aspects of 
SSc, including skin disease, although this ben-
efit is rather slow and modest (4, 5). There is as 
yet no trials of IVIG in SSc digital ischemia.
A vital part of the evaluation of patients with 
SSc is characterization of the autoantibody 
profile, both for diagnostic and prognostic 
purposes. Our patient was positive for U1RNP, 
associated with overlap SSc syndromes; these 
affect around one-fifth of SSc cases (6). Of note, 
ANCA-associated vasculitis has been described 
in association with SSc and U1RNP patients (7). 
Originally, the U1RNP antibody positivity was 
thought to imply a milder disease course as in 
the subset of patients first described in 1972 
when the term “mixed connective tissue dis-
ease” was proposed (8). These patients exhib-
ited overlap features of SSc, SLE, RA, and my-
ositis, but they were thought to have minimal 
pulmonary, renal, and cerebral involvement 
and a good prognosis. Since that description, 
however, further evidence has suggested 
that these patients often do not follow a mild 
course, but tend to evolve to a more defined 
disorder; in fact, pulmonary involvement is 
now recognized to be present in around 75 % 
of cases, in particular pulmonary hypertension 
and interstitial lung disease (9). The original 
group of patients had a mortality of 36.4% at 
12 years (10).
A notable aspect of this case was the success 
of conservative medical strategies over major 
surgical intervention in the treatment of this 
patient’s hand necrosis. The role of surgery 
in the management of SSc digital ischemia is 
controversial; while amputation for areas of 
wet gangrene is unavoidable, it is recognized 
that dry gangrenous areas tend to autoampu-
tate with less resultant tissue loss (11), as in the 
case presented. With medical treatment, the 
proximal portion of the patient’s hands and 
digits that had initially appeared non-viable 
slowly improved, and debridement only to 
the level of the metacarpophalangeal joints 
was eventually required. He retains a degree of 
manual function as a result.
This was an unusual case of severe gangrene 
in an overlap connective tissue disease patient. 
The U1RNP antibodies may not imply a mild 
disease course in this group. IVIG may warrant 
further investigation as a therapeutic tool in 
critical digital ischemia refractory to conven-
tional treatment. Medical strategies can be 
pursued over major surgery in this setting as 
long as necrosis remains dry.
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